Roth Capital Maintains Buy on Cingulate, Lowers Price Target to $14
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Roth Capital analyst Boobalan Pachaiyappan maintains Cingulate (NASDAQ:CING) with a Buy and lowers the price target from $16 to $14.
Roth Capital analyst Boobalan Pachaiyappan maintains Cingulate (NASDAQ:CING) with a Buy and lowers the price target from $16 to $14.